SCHEMBL16845536

SCHEMBL16845536

NS(=O)(=O)c1ccc([C@H]2C[C@@H]2CNc2ccc(F)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRNA7 P36544 1/20 0.50
▸ CA1 P00915 10/20 0.48
▸ CA2 P00918 10/20 0.48
▸ SLC6A2 P23975 2/20 0.48
▸ HTR2A P28223 2/20 0.48
▸ HTR2C P28335 2/20 0.48
▸ SLC6A4 P31645 2/20 0.48
▸ HTR2B P41595 2/20 0.48
▸ SLC6A3 Q01959 2/20 0.48
▸ CA9 Q16790 8/20 0.47
▸ CA12 O43570 7/20 0.47
▸ CA7 P43166 2/20 0.47
▸ CA4 P22748 2/20 0.47
▸ PTGS2 P35354 1/20 0.46
▸ LMNA P02545 2/20 0.43
▸ HTT P42858 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.41
▸ GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16819925 1.00 CHRNA7 (0.50) CHRNA7CA1CA2SLC6A2HTR2A
SCHEMBL16819933 1.00 CHRNA7 (0.50) CHRNA7CA1CA2SLC6A2HTR2A
SCHEMBL15557242 0.86 SOS1 (0.53) CHRNA7CA1CA2HTR2AHTR2C
SCHEMBL16845429 0.86 SOS1 (0.53) CHRNA7CA1CA2HTR2AHTR2C
SCHEMBL16845411 0.83 CHRNA7 (0.42) CHRNA7SLC6A2HTR2AHTR2CSLC6A4
SCHEMBL20707756 0.82 HTR2C (0.54) SLC6A2HTR2AHTR2CSLC6A4HTR2B
SCHEMBL20707739 0.79 HTR2C (0.50) SLC6A2HTR2AHTR2CSLC6A4HTR2B
SCHEMBL16819968 0.77 SOS1 (0.38) CHRNA7CA1CA2SLC6A2HTR2A
SCHEMBL16819916 0.77 SOS1 (0.38) CHRNA7CA1CA2SLC6A2HTR2A
SCHEMBL18361588 0.76 CA1 (0.66) CA1CA2CA9CA12CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9790173-B2 Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof-I MERCK SHARP & DOHME CORP. (US) 2017-10-17 — — US disclosed
US-20170158628-A1 ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF-I MERCK SHARP & DOHME CORP. (US) 2017-06-08 — — US disclosed
US-20150175534-A1 Alpha-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEROF-I MERCK SHARP & DOHME CORP. 2015-06-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170158628-A1 ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF-I CHRNA7, CHRNA5, CHRNA6 CHRNA7 1/4885CA1 1704/4885CA2 2747/4885
US-20150175534-A1 Alpha-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEROF-I CHRNA7, CHRNA6, CHRNA5 CHRNA7 1/4885CA1 2274/4885CA2 2752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback